Pallas Capital Advisors LLC purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,063 shares of the company’s stock, valued at approximately $66,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Virtus ETF Advisers LLC raised its stake in shares of Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after acquiring an additional 3,061 shares during the period. Harbor Advisors LLC purchased a new position in Kura Oncology in the fourth quarter valued at about $87,000. E Fund Management Co. Ltd. acquired a new position in shares of Kura Oncology during the fourth quarter worth about $90,000. Corton Capital Inc. acquired a new position in shares of Kura Oncology during the fourth quarter worth about $99,000. Finally, Optimize Financial Inc purchased a new stake in shares of Kura Oncology in the fourth quarter worth about $100,000.
Wall Street Analysts Forecast Growth
KURA has been the topic of several recent research reports. UBS Group reduced their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. JMP Securities reiterated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a research note on Wednesday, June 4th. Wall Street Zen downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Cantor Fitzgerald raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research report on Monday, April 28th. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $24.50.
Kura Oncology Stock Down 3.3%
KURA stock opened at $6.44 on Friday. The firm has a market cap of $557.54 million, a price-to-earnings ratio of -2.73 and a beta of 0.40. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $23.48. The firm has a fifty day moving average price of $6.14 and a two-hundred day moving average price of $7.49. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.
Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. Research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Read More
- Five stocks we like better than Kura Oncology
- What Are Dividend Achievers? An Introduction
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- What Are Earnings Reports?
- Alphabet Enters a Bull Market: Is It Time to Buy?
- Overbought Stocks Explained: Should You Trade Them?
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.